231
Participants
Start Date
January 7, 2014
Primary Completion Date
December 29, 2016
Study Completion Date
December 29, 2016
ornithine phenylacetate
Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
placebo intravenous infusion
Placebo for continuous IV infusion that is visually identical to the experimental product
Brussels
Brussels
Vienna
Auckland
Vienna
Brussels
Sofia
Sofia
Copenhagen
Hvidovre
Kingswood
Leuven
Melbourne
Parkville
Melbourne
Debrecen
Adelaide
Bedford Park
Gyula
Esbjerg
Kaposvár
Pécs
Aarhus
Graz
Ghent
New York
New York
Safed
Prague
Buffalo
Pittsburgh
A Coruña
Girona
Philadelphia
Philadelphia
Philadelphia
Rozzano
Milan
Hamburg
Bethesda
Baltimore
Baltimore
Richmond
Bergamo
Chapel Hill
Madrid
Madrid
Madrid
Málaga
Charleston
Atlanta
Atlanta
Toulouse
Bordeaux
Miami
Pessac
Pontevedra
Nashville
Grenoble
Santander
Jackson
Bologna
Seville
Columbus
Valencia
Petah Tikva
Ramat Gan
Florence
Tartu
Iowa City
Iowa City
Bonn
Milwaukee
Mainz
Minneapolis
Lille
Glenview
Chicago
Chicago
Chicago
Tel Aviv
Columbia
Heidelberg
Lyon
New Orleans
New Orleans
San Giovanni Rotondo
Little Rock
Dallas
Dallas
Dallas
Dallas
Paris
Houston
Freiburg im Breisgau
Phoenix
Phoenix
La Roche
Los Angeles
Los Angeles
Palermo
Coronado
San Francisco
San Francisco
Villejuif
Seattle
Seattle
Moscow
Moscow
Moscow
Moscow
Samara
Haifa
Haifa
Jerusalem
New Haven
Boston
Boston
Newark
Brno
Ústí nad Labem
Nice
Hanover
Halle
Leipzig
Roma
Leiden
Maastricht
Barcelona
Barcelona
Barcelona
Lead Sponsor
Ocera Therapeutics, Inc.
INDUSTRY